CD4 and neoplasm: Since MHC class II-restricted antigens naturally recognized by CD4+ T cells were poorly presented on most tumor cells (42), CD4+ T cells engineered with an MHC class I-restricted TCR have been evaluated as an attractive strategy to exert antitumor effector functions.